You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Medtronic completed its separation of MiniMed Group, Inc. At its October 15, 2026 Annual General Meeting, shareholders elected twelve directors, ratified PricewaterhouseCoopers LLP as auditor and approved executive compensation.
Medtronic plc’s Exchange Offer expired October 9, 2026; Medtronic accepted 55,032,401 Medtronic Ordinary Shares in exchange for 252,813,348 newly issued MiniMed Common Stock, disposing of its remaining interest in MiniMed.
Medtronic’s Exchange Offer expired October 9, 2026 and was oversubscribed; it intends to accept 55,032,401 Medtronic Ordinary Shares for 252,813,348 MiniMed Common Stock, with an estimated preliminary proration factor of approximately 18.3%.
Medtronic set the final exchange ratio at 4.5939 MiniMed Group, Inc. shares per ordinary share for an offer covering up to 225,361,295 shares, approximately 80.1% of outstanding MiniMed shares.
Useful current figures from the complete screener profile.
* Q4 derived as the full year minus Q1 to Q3.
TL;DR. Medtronic reported Q1 FY27 revenue of $9.8B with 13.7% organic growth well ahead of expectations and raised its FY27 organic revenue growth guidance by 50bps to 7.25%-7.75% and FY27 EPS guidance to $5.94-$6.00, while announcing new strategic investments in Cornerstone Robotics and Pi-Cardia and continued 88% growth in Cardiac Ablation Solutions.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Ten of the 25 most-shorted S&P 500 stocks have a stock deal, convertible notes, forward share sales or a mandatory convertible in their SEC filings, each a standard source of hedged short selling. Kimberly-Clark and Medtronic show how fast deal trades can push a position up.
Executives at non-tech S&P 500 companies talked about AI on 61.2% of their earnings calls last quarter, up from 33.8% in early 2024. Only 9.0% of calls put a number on what AI saved, sped up or earned, and the most common figure is a savings target for a company-wide cost program.
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Illustrative technical + ownership context — a signal mix, not investment advice.
| Metric | Latest | Period | YoY |
|---|---|---|---|
| Free Cash Flow non-GAAP | $1.29B | Three months ended July 31, 2026 | — |
GAAP → non-GAAP reconciliationGAAP Net cash provided by operating activities 1.79B
-503M Additions to property, plant, and equipment
= Free Cash Flow 1.29B
|
|||
| Non-GAAP diluted EPS non-GAAP | $1.45 | Q1 FY27 | — |
| Non-GAAP net income non-GAAP | $1.86B | Q1 FY27 | — |
| Non-GAAP operating margin non-GAAP | 23.7% | Q1 FY27 | — |
| Non-GAAP operating profit non-GAAP | $2.32B | Q1 FY27 | — |
| Organic revenue growth non-GAAP | 13.7% | Q1 FY27 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
MDT
this stock
Medtronic plc
|
$131.57B | +7.1% | +8.4% | 25.3 | 1.8% |
|
ABT
Abbott Laboratories
|
$187.95B | -13.4% | +5.7% | 40.5 | 1.1% |
|
SYK
Stryker Corp
|
$117.88B | -11.9% | +11.2% | 33.0 | 1.7% |
|
BSX
Boston Scientific Corp
|
$64.27B | -53.5% | +12.5% | 18.8 | 2.4% |
|
EW
Edwards Lifesciences Corp
|
$61.61B | +25.7% | +11.5% | 60.5 | 1.6% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
Medtronic completed its separation of MiniMed Group, Inc. At its October 15, 2026 Annual General Meeting, shareholders elected twelve directors, ratified PricewaterhouseCoopers LLP as auditor and approved executive compensation.
View| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| MDT | +1.0% | +8.6% | +32.6% | +6.6% | +7.1% |
| SPY | +2.6% | -1.2% | +0.5% | -0.2% | +10.6% |
| vs SPY | -1.6% | +9.7% | +32.1% | +6.7% | -3.5% |
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.
